(TSX:BOIL),(OTC US:BEOLF),(Other OTC:BEOLF),(Boerse Frankfurt – Freiverkehr:UH9),(Boerse Frankfurt – Freiverkehr:UH9.F), VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company“), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste and enhancing sustainability, today announces the […]

Austin, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) — Made In Cookware, the premium cookware brand trusted by professional chefs and home cooks alike, today announced a new partnership with Light Labs, an ISO 17025-accredited third-party testing laboratory, to independently evaluate the safety of its cookware. As part of the initiative, Light Labs tested Made In's

(NASDAQ:BIVI), – Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone – – Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 – CARSON CITY, Nev., Jan. 08, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for

Durham, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) — AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated in the United States Therapy granted United States Food and Drug Administration (FDA) Fast Track and Orphan Drug designations Pompe disease is a rare genetic metabolic disorder that without early detection and treatment can lead to premature

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Coralogix, the leading full-stack observability platform, today announced that the U.S. Department of Education's Federal Student Aid will serve as the official sponsoring agency for the company's pursuit of a FedRAMP Moderate authorization. Coralogix will be the first AI observability platform to achieve this milestone. Upon earning this

(Madrid:ORY.MC),(Boerse Stuttgart – Freiverkehr:ORN),(Madrid:ORY),(Boerse Stuttgart – Freiverkehr:ORN.SG), MADRID and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: 9th Sachs Annual Neuroscience Innovation Forum, January 11Location: Marines' Memorial

Washington, D.C., Jan. 08, 2026 (GLOBE NEWSWIRE) — Washington, D.C. — January 8, 2026 — Blue Star Families (BSF), the nation's largest nonprofit dedicated to supporting military and veteran families, announces the appointment of seven new members to its National Advisory Board. These new members offer a powerful mix of expertise, innovative viewpoints, and a

ROSCREA, Ireland, Jan. 08, 2026 (GLOBE NEWSWIRE) — Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company focused on advancing new therapies for patients with significant unmet needs in gastrointestinal (“GI”) disorders, announced that the United States Patent and Trademark Office (“USPTO”) has granted its sixth U.S. patent for naronapride. The patent (Patent No. 12,391,684) encompasses

(NASDAQ:ALGM), MANCHESTER, N.H., Jan. 08, 2026 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (Nasdaq: ALGM) today announced it plans to release financial results for its third quarter fiscal year 2026 prior to the market open on Thursday, January 29, 2026. Following the press release, Mike Doogue, President and Chief Executive Officer, and Derek D'Antilio, Executive Vice

StoneX Announces Strategic Partnership with Enhanced Digital Group and Leads Series A Funding Round GlobeNewswire January 08, 2026 NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — StoneX Group Inc. (“StoneX”; NASDAQ: SNEX) and Enhanced Digital Group Inc. (“EDG”) announced today that StoneX Digital, a division of StoneX, and EDG have entered into a strategic partnership